Ethical Issues in Cell and Gene Therapy
The global market for cell and gene-based therapies is expected to surpass the $20 billion USD mark by 2025, with an annual growth rate of 21%. The main targets for cell – based therapies are high impact disease areas with significant incurable needs, including cancer, heart disease, neurodegenerative diseases, musculoskeletal disorders and autoimmune diseases. Gene therapies should then not be rushed to market, but companies should gather the required data about the impact of therapy in human community with the appropriate duration of follow-up to allow proper evaluation by payers. In addition, it is key to think about potential reimbursement of the techniques and also the pricing strategies, including risk sharing, as soon as the early clinical development phase
- Ethical Issues in Stem Cell Research
- Key Ethical Issues in Embryonic Stem Cell
- IPR
- Biosafety and rDNA Guidelines
- Governing Stem Cell Therapy and Funding
Related Conference of Ethical Issues in Cell and Gene Therapy
21th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
Ethical Issues in Cell and Gene Therapy Conference Speakers
Recommended Sessions
- Advanced Gene Therapeutics
- Bioengineering Therapeutics
- Cell and Gene Therapy for Rare & Common Diseases
- Cell Culture and Bioprocessing
- Cell Science and stem cell research
- Cell Therapy
- Cell Therapy for Cardiovascular and Neurological Disorders
- Clinical Trials on Cell & Gene Therapy
- Ethical Issues in Cell and Gene Therapy
- Gene Therapy
- Genetics & Genomic Medicine
- Genome Editing
- Markets & Future Prospects for Cell & Gene Therapy
- Molecular Basis of Epigenetics
- Nano Therapy
- Regulatory and Safety Aspects of Cell and Gene Therapy
- Stem Cell Research
- Stem Cell Therapies
- Tissue Engineering & Regenerative Medicine
- Viral Gene Therapy
Related Journals
Are you interested in
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)